Sales of Shingrix, the shingles vaccine, increase at Boots as more people aged over 50 seek the jab following reports and studies suggesting it may lower the risk of developing dementia.
Both outlets focus on the same theme: customers are turning out in large numbers after claims that the vaccine could reduce dementia risk by up to 20 percent. The articles link this growth in demand to the vaccine’s reported association with potential cognitive benefits rather than its standard purpose of preventing shingles.
While the reports emphasize consumer uptake and the stated dementia-risk reduction figure, they do not provide detailed context on how the claim is derived, the nature of the evidence, or whether health authorities consider the dementia angle as established medical guidance. The emphasis therefore differs mainly in presentation—highlighting the surge in sales and the “up to 20%” figure—rather than challenging the underlying claim.
